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Abstract
Background: Prisoners constitute a high-risk population, particularly for infectious diseases. The aim of this study
was to estimate the level of infectious risk in the prisons of five different European countries by measuring to what
extent the prison system adheres to WHO/UNODC recommendations.
Methods: Following the methodology used in a previous French survey, a postal/electronic questionnaire was sent
to all prisons in Austria, Belgium, Denmark and Italy to collect data on the availability of several recommended
HIV-HCV prevention interventions and HBV vaccination for prisoners. A score was built to compare adherence to
WHO/UNODC recommendations (considered a proxy of environmental infectious risk) in those 4 countries. It ranged
from 0 (no adherence) to 12 (full adherence). A second score (0 to 9) was built to include data from a previous French
survey, thereby creating a 5-country comparison.
Results: A majority of prisons answered in Austria (100 %), France (66 %) and Denmark (58 %), half in Belgium (50 %)
and few in Italy (17 %), representing 100, 74, 89, 47 and 23 % coverage of the prison populations, respectively. Availability
of prevention measures was low, with median adherence scores ranging from 3.5 to 4.5 at the national level. These
results were confirmed when using the second score which included France in the inter-country comparison. Overall,
the adherence score was inversely associated with prison overpopulation rates (p = 0.08).
Conclusions: Using a score of adherence to WHO/UNODC recommendations, the estimated environmental infectious
risk remains extremely high in the prisons of the 5 European countries assessed. Public health strategies should
be adjusted to comply with the principle of equivalence of care and prevention with the general community.
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Background
“Prison health is public health” [1]. The burden of ill-
nesses, particularly infectious diseases, is heavier in the
prison population than in the general population, with
high prevalences of HIV, HCV and tuberculosis, as well
as higher rates of mental disorders, including drug/alco-
hol use disorders [2]. The risk of prisoners transmitting
disease is high as they are in constant contact with the
general community through visitors, staff and because a
considerable proportion of them can cycle in and out of
prison. National strategies to control transmission risks
should include prisons [3]. Despite being adopted in sev-
eral countries, the principle of equivalence in health, in-
cluding prevention, between the prison system and the
general community is rarely implemented in reality [4, 5].
For example, although France adopted the principle in
1994, the ANRS-PRI2DE survey (2009–2010), which mea-
sured the level of adherence to national and WHO/
UNODC guidelines, revealed a gap between the official
recommendations and their application in French prisons
[6]. Data on health policy implementation in general in
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the prison setting are sparse, and conducting research to
explore related issues is difficult [7–9].
The main objective of this international survey was to
compare the levels of environmental infectious risk in pris-
oners between 4 different countries, by measuring to what
extent prisons in these countries adhere to international
recommendations for HIV prevention. This measurement
was achieved by computing an adherence score which was
modified to take into account the latest international rec-
ommendations. We also aimed to create a 5-country com-
parison, in order to include France, by creating a second
adherence score.
The study’s secondary objective was to identify which
particular characteristics of prison settings and peniten-




A nationwide survey targeting all prisons in each of the
following 4 European countries was conducted between
June 2013 and April 2014: Belgium (35 prisons), Austria
(28 prisons), Denmark (50 prisons) and Italy (205
prisons). A previous survey in France was conducted
between November 2009 and May 2010 and targeted all
French prisons (170 prisons).
In order to estimate "environmental" infectious risk,
an electronic/postal survey questionnaire focusing pri-
marily on the availability of HIV-HCV preventive mea-
sures and HBV vaccination for prisoners was sent to
the heads of medical units in all the prisons in all 5
countries (in 2009–2010 for France, in 2013–2014 for
the other 4 countries).
More specifically, the questionnaire collected data about
the structural characteristics of the prisons and assessed
the availability of different specific prevention measures.
The dimensions explored were related to the 10 following
interventions recommended by WHO/UNODC [10, 11]:
Bleach, Condoms and lubricants, Opioid Substitution
Treatment (OST), Information-Education-Communication
(IEC), Blood-borne virus (BBV) testing, HBV vaccination,
Post-exposition Prophylaxis (PEP), Needle/syringe ex-
change programs (NEP), access to ARV and prevention
measures for tattooing/piercing. Data on prison character-
istics included: 1) type of structure (remand centre, prison,
security prison and juvenile prison – some prisons in-
cluded several types of structures); 2) gender of the prison
population (male and/or female inmates); 3) number of
prisoners on the day of the study; 4) total numbers of
sanitary staff, doctors, nurses, security staff, and social
workers working in the prison; 5) number of full-time doc-
tors and nurses working in the prison; 6) existence of con-
sultation service for HIV, HCV/HBV and psychiatric
consultation, and frequency of consultation (every week,
every 2 weeks, etc.); 7) presence of any non-governmental
organization (NGO) involved in harm reduction (HR) and
care for drug users in the prison. We also collected the fol-
lowing data from the council of Europe’s annual penal
statistics (Space project - http://wp.unil.ch/space/) which
reflect penal policy at the national level: average national
levels for penitential density for 100 places (this provides a
measure of prison overpopulation), percentage of prisoners
who were sentenced primarily for drug offences, prisoner
security staff member ratio, and the ratio between pris-
oners and other professionals working in prison.
The survey was implemented in all 24-hour incarcer-
ation prisons at the national level (all semi-liberty prisons
and all other penal alternatives to imprisonment were ex-
cluded). Juvenile detention centres receiving only minors
were excluded.
Definition of the scores of adherence:
We used two documents providing official international
recommendations for interventions to prevent HIV and
other infectious diseases’ transmission in prison settings
to create adherence scores:
 The first was “Effectiveness of interventions to
address HIV in prisons”, written by the WHO in
2007, in collaboration with UNAIDS and UNODC,
which is the most detailed document on HIV
prevention in prison settings [10]. The purpose of
this recommendation was to document and define
the conditions required to implement all interventions
with proven efficacy for HIV- and HCV-transmission
prevention in prison settings.
 The second document was “HIV prevention,
treatment and care in prisons and other closed
settings: a comprehensive package of interventions”,
written by the UNODC in 2012, in collaboration
with UNAIDS, WHO, ILO and UNDP. It describes
15 key interventions to prevent HIV and viral
hepatitis transmission in prison settings [11]. It is
shorter than its WHO counterpart, but lists all current
(as of 2015) interventions to implement in prison
settings, except bleach, whose efficacy in preventing
HIV-HCV in the prison context has not been proven.
In particular, it describes three important measures,
among others, which were not clearly detailed in
the 2007 WHO document: access to ARV, HBV
vaccination and prevention measures for tattooing
and piercing.
In order to evaluate the implementation of HIV preven-
tion and other HR measures in prisons and to estimate
the level of environmental infectious risk exposure in the
5 different countries investigated, two scores of adherence
to HIV preventive measures were built: the first, using the
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second document above, reflected the most recent recom-
mendations for adherence to WHO/UNODC recommen-
dations (2012), and ranged from 0 (no adherence) to 12
(full adherence). It was used to compare adherence be-
tween Austria, Denmark, Belgium and Italy. The second
score, constructed to create a 5-country comparison, in-
cluded data from the 2009–2010 French ANRS-PRI2DE
survey and ranged from 0 to 9. This different scoring sys-
tem was required because at the time of the French survey,
only the 2007 WHO recommendations (first document
above) were available and did not include the following 3
recommendations: accesss to ARV, HBV vaccination and
prevention measures for tattooing and piercing.
Table 1 shows items corresponding to international rec-
ommendations and how adherence to each specific rec-
ommendation was scored. For each of the two adherence
scores constructed, a global score was built, by summing
the subscores corresponding to each recommendation.
Each subscore ranged from 0 to 1 (i.e., 0, 0.5, 1) with the
exception of the scores for opioid substitution treatment
and access to condoms. Subscores for these two measures
ranged between 0 and 2, in order to give them a higher
weighting, given that their effectiveness in HIV prevention
is considered very high [10]. Therefore, potential overall
scores for adherence ranged from 0 to 12 (10 recommen-
dations) for the 2013 survey for Austria, Belgium,
Denmark and Italy, and from 0 to 9 (7 recommendations)
for the 2009 French survey (as the 3 abovementioned rec-
ommendations were not assessed). For each subscore, we
computed the proportion of prisons in each country ad-
herent to international recommendations. In line with the
2007 WHO recommendations, we set the subscores for
IEC and Testing/counseling at zero in both surveys, as
NEP was not available in all prisons (“prisoners must be
provided with the prevention measures that enable them
to act upon the information they receive, such as condoms
Table 1 Scoring method for computing adherence to international recommendations in prisons (PRIDE Europe)
International Recommendations Score
Information-Education-Communication •Availability of Information/education at entry or during prison stay 0.5
•Peer education programs available 0.5
•AND availability of clean injecting equipment + condoms (0 if not)a 1
Testing - Counseling •Testing for HIV, HBV, HCV systematically proposed at entry (RC) and during
prison stay (all prisons)
•AND availability of clean injecting equipment + condoms (0 if not)* 1
Condoms - Lubricants •Condoms available in various locations 1
•Water-based lubricants available 0.5
•Male condoms and lubricants accessible and female condoms
accessible for prisons with female prisoners
0.5
2
Opioid Substitution Therapy •Induction at entry (RC) + induction during prison
stay + continuity of OST at entry (all prisons)
1
•No ceiling dosage 0.5
•No buprenorphine crushing or dilution 0.5
2
Bleach •At least 2 locations/access for bleach inside prison (penitentiary distribution,
purchasable inside prison, available in medical unit)
•AND Intelligible information for HR purposes accessible for all prisoners 1
HBV Vaccinationb •Systematic HBV vaccination proposal for all seronegative prisoners 1
Post-Exposition Prophylaxis •All prisoners informed of PEP availability inside prison 1
Needle Exchange Programs •NEP are available 1
ARV treatmentb •ARV are accessible 0.5
•Prescriptions follow national guidelines 0.5
1
Prevention of transmission through tattooing, piercingb •Existing initiatives aiming at reducing the sharing and reuse of equipment
used for tattooing, piercing and other forms of skin penetration
1
TOTAL 12
aCondition defined in the 2007 WHO recommendations for IEC and Testing/counseling: “prisoners must be provided with the prevention measures that enable
them to act upon the information they receive, such as condoms and clean injecting equipment”. bThese interventions were not included in the international
scoring calculation in the 2009 French ANRS-PRI2DE survey
Bold numbers are the total value for each subscore
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and clean injecting equipment”). In the first analysis,
which compared adherence in Austria, Belgium, Denmark
and Italy, only global scores (ranging from 0 to 12) were
taken into account (hereafter Europe 4 analysis or E4). In
the second analysis, which included data from the 2009
French survey to create a 5-country comparison , global
scores (ranging from 0 to 9) were used, (hereafter Europe
5 analysis: E5).
Statistical analysis
In the E4 analysis, a Chi-square test or Fisher exact test
(when at least one cell contained fewer than 5 observa-
tions), was used to measure the association between ad-
herence to each of the 10 interventions recommended
by WHO/UNODC. The score as a continuous variable
was also compared using the non-parametric Kruskal-
Wallis test.
Univariate linear regression models were used to as-
sess the impact of each prison characteristic and na-
tional penal characteristics (e.g. the average number of
prisoners per security staff member) on the level of ad-
herence to international recommendations.
As there is no participation of human subjects in the
“PRIDE Europe” project, the Good Clinical Practice (inter-
national ethical and scientific quality standard for design-
ing, conducting, recording and reporting trials that
involve the participation of human subjects – ICH Guide-
line) are not applicable and ethic committee approvals
were unnecessary.
Results
In the 2013–2014 survey, the participation rate (number
of prisons) in each of the 4 countries was as follows: 50 %
(17/34) in Belgium, 100 % (28/28) in Austria, 58 % (29/
50) in Denmark and 17 % (35/205) in Italy, representing,
respectively, 47, 100, 89 and 23 % of the total prison popu-
lation (total prison population on 1st January 2014, ac-
cording to the council of Europe’s annual penal statistics).
In the 2009 French survey, 113/171 prisons answered
the questionnaire (66 %), representing 74 % of the prison
population at that time.
Prisons with incomplete questionnaires or incoherent
data were systematically called by phone, and those with
missing data were not included in the data analysis.
The number of prisons with complete data for all the
questionnaire items was as follows: 11, 19, 29, 35 and 103
for Belgium, Austria, Denmark, Italy and France, respect-
ively. Table 2 shows the characteristics of the prisons at
the national level for the E4 analysis only. Considering the
internal validity of the study, the geographic distribution
of prisons which responded was comparable to that of
prisons which did not.
Descriptive results
E4 analysis
Table 3 shows the proportion of prisons, in the E4 ana-
lysis, adhering to the international recommendations for
each subscore making up the global adherence score.
For IEC and Testing-Counseling interventions, adher-
ence scores equaled zero for the 4 countries assessed,
as no country respected the required condition of avail-
able clean injecting equipment. However, the availability
of systematic HIV testing was different across countries,
ranging from 18 % in Belgium to 100 % in Italy (p < 10-3).
Female condoms were available in approximately half of
the prisons detaining female prisoners in Austria and
Denmark and in 82 % of similar prisons in Belgium (p =
0.04). Condoms were not available in any Italian prison.
Bleach was not accessible in Italy. In Belgium, bleach or
disinfecting tablets were provided in all prisons, but only
at one location. The systematic proposal of HBV vaccin-
ation was rare, except in Italy, where it was proposed
in half of the prisons. No information about the avail-
ability of Post-Exposition Prophylaxis was provided to
inmates in Belgian prisons and was very infrequent in
Austria. Instead such information was available in
most Italian prisons. ARV were accessible in all prisons
in all countries, except Italy, where only 89 % of
prisons provided ARV. Interventions for the preven-
tion of transmission through tattooing or piercing was
never or rarely implemented in prisons in the four
countries studied.
At the prison level, in the E4 analysis, the adherence
scores to international recommendations ranged from
0.5 to 7.0, with a maximum theoretical score of 12.
Figure 1 represents the mean, median, minimum and
maximum scores and interquartile range (IQR) of the
global score of adherence to international recommen-
dation per country (E4 analysis).
E5 analysis
In the 2009 French ANRS-PRI2DE survey, the French
median [IQR] adherence score to international recom-
mendations was 2.5 [1.5; 3.5]. After adjustment for the
scoring system used in the French survey (E5 analysis),
median [IQR] scores for Austria, Denmark, Belgium
and Italy were 3.5 [2.0; 4.5], 2.5 [2.0; 3.0], 3.0 [2.5; 3.5]
and 1.5 [1.5; 2.0], respectively (Fig. 2). Furthermore, in
the E5 analysis, Austria has the highest median score
(3.5, [IQR] = [3.5-6]). Denmark, France and Italy pre-
sented a significantly lower score of adherence to
international recommendations when compared with
Austria (Table 4).
Regressions analysis
With respect to prison characteristics (Table 5), the uni-
variate linear regression in the E4 analysis shows that in
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Belgium, the lower the number of security staff per pris-
oner, the higher the score of adherence to the inter-
national recommendations.
In Austria, mixed prison institutes with separate male
and female areas had a higher level of adherence (coefficient
(95 % CI) = −1.72 (−2.52 ; −0.92); p < 10-3) than their single
Table 2 E4 analysis- Characteristics of the prisons at the national level
Belgium (N = 17) Austria (N = 27) Denmark (N = 29) Italy (N = 35)
number of prisoners on the day of the study 6046 8724 3361 14229
number of prisoners on the day of the study per prison - Mean (min-max) 356 (50–1126) 312 (58–1146) 116 (14–489) 407 (30–1519)
number of prisoners on the day of the study per prison- n(%)
<100 2 (11.8) 3 (10.7) 17 (58.6) 5 (14.3)
[100-350[ 9 (52.9) 14 (50.0) 11 (37.9) 15 (42.9)
[350-600[ 2 (11.8) 9 (32.1) 1 (3.4) 9 (25.7)
≥600 4 (23.5) 2 (7.1) 0 (0.0) 6 (17.1)
Number of personnel available / prison - Mean (min-max)
Sanitary staff 14 (3–48) 10 (2–69) 5 (1–36) 24 (6–75)
Doctors 3 (1–7) 5 (1–28) 2 (1–7) 14 (3–43)
Nurses 10 (1–36) 5 (1–44) 3 (0–19) 10 (2–34)
Security staff 254 (42–707) 109 (22–421) 77 (11–460) 211 (30–950)
Social workers 7 (1–18) 4 (1–12) 2 (1–8) 5 (1–17)
Number of personnel available/100 prisoners - Mean (min-max)
Sanitary staff 4 (2–12) 4 (1–43) 5 (2–18) 8 (2–37)
Doctors 1 (0.4-6) 2 (0.4-8) 2 (0.4-7) 5 (1–23)
Nurses 3 (1–6) 2 (0.2-28) 1 (0–5) 3 (1–13)
Security staff 70 (48–86) 37 (27–74) 64 (34–170) 29 (17–160)
Social worker 2 (0.4-7) 2 (1–7) 3 (0.4-9) 2 (1–3)
Available Consultation- n(%)
HIV (yes vs. no) 2 (11.8) 28 (100) 28 (95.6) 30 (85.7)
HCV/HBV (yes vs. no) 2 (11.8) 28 (100) 28 (95.6) 30 (85.7)
Psychiatric (yes vs. no) 14 (82.4) 26 (92.9) 25 (86.2) 35 (100)
Attendance of any NGO (yes vs. no) 7 (50) 5 (19.2) 0 (0) 11 (31.4)
Type- n(%)
RC only 5 (29) 16 (55) 30 (86)
PS only 5 (29) 10 (36) 3 (11) 5 (14)
SPS only 1 (3)
JUV only




RC-PS- SPS 2 (12) 1 (3)
RC-PS- SPS-JUV 12 (43)
Gender- n(%)
Male 12 (71) 13 (46) 3 (10) 18 (56)
Female 1 (6) 1 (4) 0 0
Mixed 4 (24) 14 (50) 26 (90) 14 (54)
HIV: Human Immunodeficiency Virus; HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; NGO: Non-Governmental Organization; RC: remand center; PS: prison for
sentenced; SPS: Security prison for sentenced; JUV: juvenile prison center
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gender counterparts. The type of institute (remand centre,
prison, security prison, juvenile prison centre) was not asso-
ciated with adherence level in any country.
Considering data extracted from the Council of Eur-
ope’s annual penal statistics, one national characteristic
which was moderately associated (p = 0.08) with adher-
ence to international recommendations (5 countries
analysis) was penitential density per 100 places
(Table 6). The higher the penitential density per 100
places (coefficient (95 % CI) = −0.02 (−0.04; −0.002);
Table 3 E4 analysis- proportion of adherence to the different subscores among all participating prisons (n = 109)
Belgium (N = 17/35) Austria (N = 28/28) Denmark (N = 29/50) Italy (N = 35/205) P*
Information-Education-Communication 0 0 0 0
• Availability of Information/education
at entry or during prison stay
15 (88.2) 28 (100.0) 3 (10.3) 13 (37.1) <10−3
• Peer education programs available 4 (23.5) 2 (7.1) 4 (13.8) 1 (2.9) 0.07
• Availability of clean injecting
equipment + condoms
0 0 0 0
Testing – Counseling 0 0 0 0
• Testing for HIV, HBV, HCV systematically
proposed at entry (RC) and during
prison stay (all prisons)
3 (17.7) 11 (39.3) 8 (27.6) 35 (100.0) <10−3
• Availability of clean injecting
equipment + condoms
0 0 0 0
Condoms - Lubricants 9 (52.9) 8 (28.6) 2 (6.9) 0 (0.0) 0.002 ł
• Condoms available in various locations 12 (70.6) 14 (50.0) 14 (48.3) 0 (0.0) 0.29 ł
• Water-based lubricants available 13 (76.5) 23 (82.1) 6 (20.7) 0 (0.0) <10-3 ł
• Male condoms and lubricants accessible
and female condoms accessible for
prisons with female prisoners
14 (82.4) 14 (50.0) 13 (44.8) 0 (0.0) 0.04 ł
Opioid Substitution Therapy 4 (23.5) 6 (21.4) 7 (24.1) 5 (14.3) 0.66
• Induction at entry (RC) + induction
during prison stay + continuity of OST
at entry (all prisons)
11 (64.7) 20 (71.4) 24 (82.8) 12 (34.3) 0.0001
• No ceiling dosage 8 (47.1) 15 (53.6) 19 (65.5) 30 (85.7) 0.05
• No buprenorphine crushing or dilution 15 (88.2) 17 (60.7) 11 (37.9) 17 (48.6) 0.002
Bleach 0 (0.0) 11 (39.3) 11 (37.9) 0 (0.0) <10−3
• At least 2 locations/access for bleach
inside prison (penitentiary distribution,
purchasable inside prison, available in
medical unit)
0 (0.0) 20 (71.4) 17 (58.6) 0 (0.0) <10−3
• Intelligible information for HR purposes
accessible to all prisoners
4 (23.5) 13 (46.4) 12 (41.4) 0 (0.0) 0.30 ł
HBV Vaccination (systematic proposal for
unprotected inmates)
0 (0.0) 4 (14.3) 3 (10.3) 18 (51.4) <10−3
Post-Exposition Prophylaxis (inmates
informed of the availability of PEP)
0 (0.0) 11 (39.3) 1 (3.5) 27 (77.1) <10−3
Needle Exchange Programs 0 0 0 0
ARV treatment 14 (82.4) 27 (96.4) 29 (100.0) 33 (94.3) 0.11
• ARV are accessible 17 (100.0) 27 (100.0) 29 (100.00) 33 (89.2) 0.24
• Prescriptions follow national guidelines 14 (82.4) 27 (96.4) 29 (100.0) 33 (94.3) 0.11
Prevention of transmission through
tattooing, piercing
2 (11.8) 0 (0.0) 5 (17.2) 0 (0.0) 0.01
Total score, median (Q1-Q3) 4.0 (3.5-4.5) 4.5 (3–6.5) 4.0 (3.0-4.5) 3.5 (2.5-4) 0.0014
*Chi-square or exact Fisher test for categorical variables, Wilcoxon-Mann–Whitney test for continuous variables
ł Excluding Italy
HIV: Human Immunodeficiency Virus; HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; NGO: Non-Governmental Organization; RC: remand center; PS: prison for
sentenced; SPS: Security prison for sentenced; JUV: juvenile prison center; OST: opioid substitution therapy; HR: Harm Reduction; ARV: Antiretroviral Treatment
Bold numbers are only to identify the total score for each subscore and is not related to its statistical value and P values are on the right column
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p = 0.08), the lower the score of adherence to inter-
national recommendations.
Discussion
To our knowledge this is the first study providing an as-
sessment of access to HIV and HCV preventive interven-
tion measures in prison settings of different European
countries. If we consider the percentages of the overall
prison population covered, participation rates for this pos-
tal/electronic survey were high in all countries (100 % in
Austria, 58 % in Denmark, 50 % in Belgium, 66 % in
France) except Italy (17 %). The main result is that median
scores of adherence to the international recommendations
for HIV and HCV prevention in prison settings were low
in the 4 countries assessed using data from 2013–2014,
ranging from 3.5 to 4.5 out of a maximum of 12 (full ad-
herence). Results in these countries mirror French data
from 2009–2010 [6]. Certainly, infectious risk prevention
does not only depend on implementing WHO/UNODC
recommended interventions, but the wide gap between
these recommendations and the reality of current inter-
national and local/national practice suggests that the
prison setting constitutes an environment where infec-
tious risk continues to remain high. When adjusting the
scoring mechanism to match that used in the 2009 French
ANRS-PRI2DE survey (E5 analysis), Austria and Belgium
have a higher adherence score than France. Denmark and
France score similarly. Italy has the lowest adherence
score. HR interventions are not very accessible (especially
HBV vaccination proposal, bleach, information about PEP
availability (except in Italy), and measures to prevent trans-
mission through tattooing or piercing). In Italy, bleach and
condoms are not available anywhere. NEP are not autho-
rized in any prison in the five countries. Associations
between structural “prison” characteristics and level of ad-
herence to international recommendations are few: in our
study, only the number of security staff per prisoner was
inversely associated with the adherence score in Belgium.
It is difficult to conclude anything from this result except
that, globally, it is impossible to identify a characteristic as-
sociated with HR policy implementation in prisons. More
interestingly, the one national structural factor inversely as-
sociated with the adherence score is prison overpopulation.
This result is even more worrying when we consider that
Fig. 1 Mean, median, min and max values and interquartile range of the global score per country (E4 analysis)
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prison overpopulation is also associated with a high suicide
rate [12] and increased incidence of certain diseases (e.g.
tuberculosis) [13]. Overpopulation has already been associ-
ated with reduced access to care [14–17]. One reason for
this is probably related to the fact that security concerns
prevail over health in overpopulated prisons. Moreover,
overpopulation also reflects the orientation of the global
penal policy of a specific country, perhaps more focused
on repression than on access to care and prevention for
offenders, in particular those who use drugs. Different
studies have already shown that repressive policies expose
drug users to HIV/HCV infection [18–24].
Considering each prevention measure individually, it is
obvious that irrespective of the country, there is an urgent
need to increase the availability of most interventions.
Some existing interventions differ from those implemented
in the general community, and seem specific to the prison
setting. One example is OST (prescribing ceiling dosages,
buprenorphine crushing/dilution mainly to avoid misuse
by inmates). Though not at all available in Italy, bleach is
provided in all Belgian prisons, but only at one location. In-
telligible information for inmates regarding the use of
bleach for HR purposes is very limited everywhere. It is im-
portant to note that in the 2012 UNODC recommenda-
tions [11], providing bleach was not one of the 15 “key
interventions” to prevent HIV. If bleach is to be used to ef-
ficiently disinfect syringes and needles in order to prevent
HIV infection in prisons, a standardized, recognized proto-
col is needed. Yet the steps required to bring about the im-
plementation of such a protocol are difficult, given the
current reality of prison life and promiscuity, and would
Fig. 2 Mean, median, min and max values and interquartile range of the global score used in the 2009 French survey per country (E5 analysis)
Table 4 E5 analysis- univariate linear regression between country
and the level of adherence to international recommendations
(n = 197)
Coef (IC95 %) p
Country
Austria 1
Belgium −0.50 (−1.25 ; 0.26) 0.20
Denmark −0.93 (−1.52 ; −0.34) 0.002
Italy −1.71 (−2.28 ; −1.14) <10−3
France −0.95 (−1.45; −0.45) 0.0002
Bold numbers have statistical significance
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Table 5 E4 analysis- univariate linear regression between prison characteristic and the level of adherence to international recommendations
Belgium (N = 11) Austria (N = 19) Denmark (N = 29) Italy (N = 35)
Coef (IC95 %) P Coef (IC95 %) P Coef (IC95 %) P Coef (IC95 %) P
Number of prisoners on the day of the study/100 0.03 (−0.14;0.19) 0.72 0.14 (−0.15;0.44) 0.33 0.06 (−0.31;0.45) 0.73 −0.01 (−0.09;0.08) 0.85
Number of personnel available/number of prisoners on the day of the study
Sanitary staff 0.09 (−27.20;27.38) 0.99 5.94 (−2.03;13.91) 0.13 −0.14 (−13.33;13.05) 0.98 2.36 (−3.17;7.89) 0.39
Doctors (*100) −0.71 (−1.48; 0.06) 0.07 0.43 (−0.05;0.91) 0.08 −0.01 (−0.24;0.22) 0.89 0.03 (−0.04;0.12) 0.42
Full time doctors (*100) – – 0.40 (−1.12;1.93) 0.59 –
Nurses (*100) −0.05 (−0.43;0.33) 0.75 0.10 (−0.02;0.22) 0.11 0.02 (−0.28;0.33) 0.89 0.05 (−0.09;0.20) 0.47
Full time nurses (*100) – – 0.09 (−0.33;0.51) 0.66 –
Security staff −5.67 (−10.92;-0.43) 0.04 6.47 (−0.75;13.70) 0.07 −0.71 (−2.09;0.66) 0.30 −0.18 (−1.15;1.52) 0.78
Social workers −10.25 (−37.30;16.80) 0.41 52.63 (−16.04;121.30) 0.12 −5.31 (−25.96;15.32) 0.60 −5.37 (−54.13;-43.57) 0.82
Available Consultation
HIV (yes vs. no) −0.11 (−1.47;1.26) 0.86 – −0.67 (−2.86;1.51) 0.53 0.17 (−0.71;1.05) 0.70
HCV/HBV (yes vs. no) −0.11 (−1.47;1.26) 0.86 – −0.67 (−2.86;1.51) 0.53 −0.30 (−1.17;0.57) 0.49
Psychiatric (yes vs. no) −1.00 (−2.67;0.68) 0.21 0.18 (−2.38;2.74) 0.89 −0.32 (−1.48;0.83) 0.60 –
Attendance of any NGO (yes vs. no) −0.41 (−1.48;0.65) 0.39 0.70 (−1.24;2.63) 0.46 – −0.55 (−1.18;-0.08) 0.08
Number of different prison types
1
2 −0.14 (−1.65;1.37) 0.83 −0.87 (−2.86;1.11) 0.36 −0.15 (−1.07;0.77) 0.74 –
3 −0.14 (−1.65;1.37) 0.83 −1.56 (−3.20;0.08) 0.06 −0.40 (−2.65;1.85) 0.72 –
Mixed male/female prison
No 1
Yes 0.02 (−0.67;0.71) 0.95 −1.72 (−2.52 ;-0.92) <10−3 0.08 (−0.62;0.78) 0.81 −0.50 (−1.13;0.13) 0.11
Type of prison
RC 1 1 1 1
PS −0.13 (−0.87;0.62) 0.73 0.70 (−0.40;1.81) 0.21 0.23 (−0.60;1.06) 0.58 0.07 (−0.82;0.95) 0.88
SPS −0.13 (−1.27;1.02) 0.82 – – −0.05 (−0.93;0.82) 0.90 – –
JUV – – 0.27 (−1.05;1.58) 0.68 – – – –
HIV: Human Immunodeficiency Virus; HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; NGO: Non-Governmental Organization; RC: remand center; PS: prison for
sentenced; SPS: Security prison for sentenced; JUV: juvenile prison center













take a long time to put in place. Furthermore, bleach is not
effective in preventing HCV transmission [25]. In the 2007
WHO/UNODC document, bleach was only considered as
an alternative to NEP when the latter was not available.
Another concern is that even though our results showed
that coverage for antiretrovirals was acceptable, some
prisons still have only limited access (ARV are not access-
ible in 10.8 % of Italian prisons,) or provide prescriptions
which do not follow the corresponding national guidelines
(17.6 % of prisons in Belgium, 5.7 % in Italy and 3.6 % in
Austria). Tattooing and piercing are common practices in
prison settings all over the world and have been clearly as-
sociated with HCV transmission [26–29]. However, associ-
ated preventive measures are very rare in the 4 countries
(i.e. excluding France) assessed. Previous experience high-
lights the need to develop such measures [30, 31].
Limitations
Some limitations need to be acknowledged. Although
self-reports and interviews serve as the only current
feasible methods to study access to prevention, they may
be affected by social desirability bias. However, while the
risk of over-reporting availability of preventive measures
was high in our study, adherence rates were low, particu-
larly in Italy, the country with the lowest participation
rate. True scores may be even lower if we consider that
the prisons included in the study may perhaps be those
most active in prevention/harm reduction issues, reflected
in health staffs’ decisions to answer the study question-
naire. In contrast, global coverage of the prison population
and geographical representativeness were satisfactory in
the survey. Second, it is also possible that physicians may
not have been sufficiently informed about the interven-
tions promoted by the prison administration in which they
worked, especially in countries where health is not the re-
sponsibility of the Ministry of Justice, such as Italy. This is
the case for France where access to prevention measures
is the responsibility of the penitentiary administration. Re-
sponse rates were different across countries despite several
electronic/postal reminders (from at least 1 reminder in
Austria to 3 in Italy) at the national level, and follow-up
calls at the prison level for prisons. Moreover, in Belgium, a
strike by sanitary staff in prisons started during the data
collection period and lasted for several months. As a conse-
quence, the survey operator had to be changed (from peni-
tentiary administration to Ghent University). In Italy, the
main explanations for the low response rate were the reluc-
tance of sanitary staff to answer the questionnaire, and the
fact that the transfer of care organization from the peniten-
tiary administration to the national health system has not
yet been fully implemented. Another difficulty in Italy is
linked to questionnaire data collection. In Denmark, the re-
sponse rate was lower in “remand centers”. One possible
explanation for this was that sanitary staff in these usually
very small prisons are external consultants with very lim-
ited interventions, in contrast to detention centers where
health interventions are more structured and come under
the responsibility of the Ministry of Justice. Nevertheless,
considering the prison environment and the design of the
survey, response rates were quite high (except for Italy).
Another possible study limitation is the weight given to
NEP in our scoring: when not available, IEC and testing
were scored zero, as per the 2007 WHO/UNODC recom-
mendations. Considering the low or even zero impact of
bleach on HIV/HCV prevention [25] and the clear conclu-
sions of several other studies on HCV prevention in
people who use drugs, the role of OST and NEP in redu-
cing HCV transmission in prison settings seems to be es-
sential. Although OST alone (methadone in particular)
is effective in preventing HCV [32, 33], combining OST
and NEP interventions increases this effectiveness [34–
37]. In a particularly high-risk environment like the
prison context, NEP should be combined with OST and
other interventions to prevent infectious diseases.
Conclusions
The most important result from this study is the low level
of adherence to international recommendations for pre-
vention interventions, which in turn is a proxy of environ-
mental risk. This risk is associated with overpopulation in
prison. As long as drug use continues to be criminalized,
drug use in prison (in particular drug injection) will re-
main a taboo subject, despite converging arguments show-
ing the existence of associated high-risk practices. While
HR interventions need to be enhanced and scaled-up in
prison settings, decriminalization of drug use, or at least
alternatives to prison for drug-using populations, are ur-
gently needed to be able to guarantee prevention and care
in line with international standards.
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